What Niche Will newer class III antiarrhythmic drugs occupy?

Current Cardiology Reports

Volumn 3, Issue 4, 2001, Pages 314-323

  Singh, Bramah N ^a   Sarma, Jonnalagedda S M ^a  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT;

HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; REVIEW;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; ATRIAL FIBRILLATION; HUMANS;

EID: 0035405773     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-001-0086-x     Document Type: Article

References (41)

1. Singh BN: Antiarrhythmic drugs: a re-orientation in light of recent developments in the control of disorders of rhythm. Am J Cardiol 1998, 81:3D-13D.
2. Singh BN: Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility. J Cardiovasc Electrophysiol 1999, 10:283-301.
3. Camm AJ, Yap Guan Yee: What should we expect from the next generation of antiarrhythmic drugs? J Cardiovasc Electrophysiol 1999, 10:317-317.
4. Wei Sun, Sarma JSM, Singh BN: Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation 1999, 100:2276-2281.
5. Singh BN: Historical development of the concept of controlling cardiac arrhythmias by lengthening repolarization: particular reference to sotalol. Am J Cardiol 1990, 65(Suppl 3):A11A.
6. Singh BN: Sotalol: current status and expanding indications. J Cardiovasc Pharmacol Therapeut 1999, 4:59-65.
7. Nattel S, Singh BN: Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions. Am J Cardiol 1999, 84:11R-19R.
8. Murray KT: Ibutilide. Circulation 1998, 97:493-497.
9. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al., for the Danish Investigations of Arrhythmia and Moratlity on Dofetilide Study group: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Eng J Med 1999, 341:857-865.
10. Fermini, B, Jurkiewicz NK, Jow B: Use dependent effect of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization block or delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol 1995, 26:259-267.
11. Salata JJ, Brooks RR: Pharmacology of azimilide dihydrochloride (NE-10064), a class III antiarrhythmic agent. Cardiovas Drug Rev 1997, 15:137-156.
12. Singh BN, Mody FV, Lopez B, Sarma JSM: Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization. Am J Cardiol 1999, 84:161R-173R, 92:1954-1968.
13. Hohnloser S, Klingenheben T, Singh BN: Amiodarone-associated proarrhythmic effects: a review with special reference to torsades de pointes tachycardia. Ann Int Med 1994, 121:529-535.
14. Lee Ks, Gibson JK: Unique ionic mechanism of action of ibutilide on freshly isolated heart cells. Circulation 1995, 92:2755-2757.
15. Ellenbogen KA, Sambler BS, Wood MA, et al.: Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and flutter: a dose-response study. J Am Coll Cardiol 1996, 28:130-136.
16. Stambler BS, Wood MA, Ellenbogen KA, et al.: Efficacy of safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996, 94:1613-1621.
17. Ellenbogen KA, Clemo HF, Stambler BS, et al.: Efficacy of ibutilide for termination of atrial fibrillation and flutter. Am J Cardiol 1996, 78:42-45.
18. Buchanan LV, Kabell G, Brunden MN, et al.: Comparative assessment of ibutilide, d-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. J Cardiovasc Pharmacol 1993, 22:540-549.
19. Naccarelli GV, Lee KS, Gibson JK, et al.: Electrophysiology and pharmacology of ibutilide. Am J Cardiol 1996, 78:12-16.
20. Oral H, Souza HJ, Michaud GF, et al.: Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide treatment. N Engl J Med 1999, 340:1849-1854.
21. Singh BN: Acute conversion of atrial flutter and fibrillation: direct current cardioversion versus intravenously administered pure class III agents. J Am Coll Cardiol 1997, 29:391-393.
22. Roden DM: Ibutilide and the treatment of atrial arrhythmias. a new drug-almost unheralded-is now available to US physicians. Circulation 1996, 94:1499-1502.
23. Stambler BS, Wood MA, Ellenbogen KA: Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing. Am J Cardiol 1996, 77:960-966.
24. Glatter K, Young Y, Chatterjee K et al.: Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients amiodarone therapy. Circulation 2001, 103:253-257.
25. Kowey PR, Vanderlugt JT, Luderer JR: Safety and risk/benefit analysis of ibutilide for acute conversion of atrial flutter and fibrillation. Am J Cardiol 1996, 78:46-52.
26. Falk RH, Pollak A, Singh SN, Friederich T for Doefitilide Investigators: Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol 1997, 29:385-392.
27. Pfizer Labs: Data on file. New York, NY.
28. Carmeliet E: Voltage-and time-dependent block of the delayed K current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther 1992, 262:809-817.
29. Jurkiewicz NK, Sanguinetti MC: Rate-dependent prolongation of action potentials by a methanesulfonanilide class III antiarrhythmic agent: specific block of rapidly activating delayed rectifier K+ current by dofetilide. Circ Res 1993, 72:75-83.
30. Singh SN, Zoble RG, Yellen L, et al., for the Dofetilide Atrial Fibrillation Investigators: Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or flutter: the symptomatic atrial fibrillation Investigative research on dofetilide (SAFIRE-D) study. Circulation 2000, 102:2383-2390.
31. Waldo AL, Camm AJ, D Ruyter H et al.: Effects of d-sotalol on mortality in patients with left ventricular function after recent and remote myocardial infarction. Lancet 1996, 348:7-12.
32. Corey AE, Al-Khalidi H, Brezovic C, et al.: Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing. Clin Pharmacol Ther 1997, 61:205-212.
33. Lamorgese M, Kirian M, Van Wagoner DR: Azimilide (NE-10064) blocks outward K currents in human atrial and ventricular myocytes. Circulation 1997, 92(8, Suppl l):I575.
34. Groh WJ, Gibson KJ, Maylie JG: Comparison of the rate-dependent properties of the class III antiarrhythmic agents azimilide (NE-10064) and E-4031: considerations on the mechanism of reverse-rate dependent action potential prolongation. J Cardiovasc Electrophysiol 1997, 8:529-536.
35. Restivo M, Hegazy M, El-Hamamy M: Antiarrhythmic efficacy of azimilide dihydrochloride on functional circus movement atrial flutter in the canine right atrial enlargement model. PACE 1996, 19(4, Part II):664.
36. Nattel S, Liu L, St George D: Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. Cardiovasc Res 1998, 37:627-635.
37. Drexler AP, Micklas JM, Brooks RR: Effects of intravenously administered NE-10064 on programmed electrical stimulation (PES)-induced ventricular arrhythmias in anesthetized infarcted dogs. FASEB J 1993, 7:A97.
38. Black SC, Butterfield JL, Lucchesi BR: Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug. J Cardiovasc Pharmacol 1993, 22:810-823.
39. Procter & Gamble Labs: Data on file.Cincinnati, OH.
40. Pritchett E, Page, R, Connolly Marcello, S and ASAP Investigators: Azimilide treatment of atrial fibrillation. Circulation 2000, 98:1-633.
41. Benditt DG, Williams JH, Jin J, et al., for the dl-Sotalol Atrial Fibrillation/Flutter Study Group: Maintenance of sinus rhythm with oral dl-sotalol therapy in patients with symptomatic atrial fibrillation and flutter: a dose-response study. Am J Cardiol 1999, 84:270.